Eli Lilly to target cancer drug developers for deals

The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the NYSE in New York

(Reuters) - Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.

"Probably because of the number of opportunities, you will see us active in oncology - that's where a lot of early stage biotech is," Ricks said.

(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting